Our comprehensive evaluation led us to draw generalizable conclusions for HNSCC, specifically that targeting BCL-xL and BCL-2 alone was effective, but did not result in consistent synergy when combined with radiation and/or cisplatin. Here, BCL2 is linked to head and neck squamous cell carcinoma.